Description
Details
HEPCINAT-LP contains polymerase inhibitors which called sofosbuvir and ledipasvir . Hepcinat-LP launched by Natco Pharma Ltd (India) and approved for treatment patients infected with HCV genotypes 1 and 4. Sofosbuvir & Ledipasvir is FDA-approved and EASL recommended treatment protocol for HCV, which does not include interferon or ribavirin. In the clinical trials have proven very high success rate of sofosbuvir in couple with ledipasvir. In one of official clinical trials involved more than 1,600 people with HCV genotype 1. The course of treatment was only 84 days. By the end of therapy 1556 patients achieved the primary target – absence of the virus. Adverse events that occurred in patients receiving sofosbuvir together with ledipasvir were mild and generally accompanied by headache and fatigue.
How Hepcinat-lp works
Sofosbuvir+ledipasvir targetly affects to specific proteins involved in viral replication and thus totally stop the disease.
